Headshot of Olga Lavrynenko, MD

Olga Lavrynenko, MD

University Medicine Associates
Schedule an appointment: 210-358-7500
Loading...
Loading...

Specialty

  • Endocrinology

Board Affiliation/Certification

  • American Board of Internal Medicine

Education

  • Kharkiv National Medical University (1998)

Residency

  • Anesthesiology/Critical Care, Kharkiv Medical Academy of Post Graduate Education (2000)
  • Internal Medicine, Texas Institute of Graduate Medical Education and Research - Laredo Medical Center (2023)

Fellowships

  • Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center (2025)

Languages

  • English
  • Russian
  • Ukrainian

Gender

  • Female

Medical Center Pavilion

4647 Medical Drive
San Antonio,TX 78229

Texas Diabetes Institute

701 S. Zarzamora Street
San Antonio,TX 78207

Insurance Accepted

  • Amerigroup
  • Blue Cross Blue Shield of Texas
  • CareLink Program
  • Children with Special Health Care Needs Program
  • Cigna - USAA Employees
  • Community First Health Plan
  • Council for Affordable Quality Healthcare
  • Coventry Health Care
  • Humana, INC
  • Medicaid
  • Medicare
  • Molina
  • Superior Health Plan Network
  • UnitedHealthcare - PPO/MK
  • WellCare - Medicare Advantage
  • WellMed Medicare/Health Springs
Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.
Olga Lavrynenko, MD
"From caring for patients with metabolic disorders in Ukraine to serving underserved communities in Laredo, Texas, and completing my endocrinology fellowship at Harvard - I am dedicated to helping patients manage diabetes, MASLD and cardiovascular disease by turning research into real improvements in their lives."
I am an endocrinologist specializing in diabetes and metabolic disease. I was inspired to go into medicine by my mother, who was a physician, along with my lifelong fascination with science. Above all, I am driven by a genuine desire to help people improve their health and quality of life.
Clinical Interests
  • Diabetes
  • Metabolic dysfunction - associated steatotic liver disease (MASLD)
  • Metabolic syndrome
  • Obesity
Philosophy of Care
My philosophy of care is rooted in the belief that everyone deserves compassionate accessible and personalized medical support.
I view health improvement as a shared effort, partnering closely with patients to create sustainable treatment plans that reflect their individual needs and goals.
Favorite Parts of Medicine
  • Seeing patients recover as they make meaningful improvements in their health
  • Working collaboratively with patients to manage complex metabolic conditions
Awards & Recognition
  • Outstanding Abstract Award, ENDO Conference (Boston, 2024)
  • Third Place, Oral Presentation - World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Los Angeles, 2023)
  • New England Endocrine Alliance Fellow Podium/Poster Award (Boston, 2023)
  • Second Place, Oral Presentation - Heart in Diabetes (New York City, 2021)
  • Third Place, Oral Presentation - World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Los Angeles, 2021)
  • Conference Award, European Association for the Study of the Liver (Vienna, 2010)
  • Honorable Mention, Oral Presentation - Heart in Diabetes (Philadelphia, 2019)
  • Honorable Mention, Oral Presentation - World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Los Angeles, 2019)
Hobbies
Outside of medicine, I enjoy traveling, reading, playing golf and staying active through Zumba and Pilates.

Journal Articles

  1. Lavynenko O, Abdul-Ghani M, DeFronzo RA. Reduced Lipotoxicity Following Triple Therapy for 3 Years in New Onset T2DM: Metabolism. Volume 153, Supplement, June 2024, 155851.
  2. Lavrynenko O., Baireddy M., Bodepudi S.,Santos H, Cortez J., Zemlianitsyna O, Sanchez F. Peritoneal and Pulmonary Tuberculosis in a Postpartum Female with Elevated Cancer Antigen 125 and Ascites. Case Rep Infec Dis 2022 Oct 26: 2022: 7012943. doi: 10.1155/2022/7012943.eCollection 2022.
  3. Lavrynenko O., Abdul-Ghani M., Alatrach M., Puckett C., Adams J., Abdelgani S., Alkhouri N., Triplitt C., Clarke G., Vasquez J., Cersosimo E., gastadelli A., DeFronzo R. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes, Obesity and Metabolism, May 2022, Volume 24, Issue 5, p.897-907 https://doi.org/10.1111/dom.14650.
  4. Lavrynenko O., Abdul-Ghani M, Santos H., DeFronzo R. Hepatic steatosis, fibrosis, and insulin resistance: implications for therapy. Metabolism Clinical and Experimental. 2022, March, Vol 128, supplemental 155018. https://doi.org/10.1016/j.metabol.2021.155018.
  5. Villafuerte D., Lavrynenko O., Qazi R., Passeri M., Sanchez F. Chronic active Epstein-Barr exacerbated by COVID-19 co-infection. International Journal of Infectious diseases. 2022; 122 ; 976-978.
  6. Lavrynenko O., Abdul-Ghani M, DeFronzo R. Carotid Atherosclerosis Is Not Related to Hepatic Steatosis or Fibrosis in EDICT. AHJ, Vol 242, 2021. p.152, https://doi.org/10.1016/j.ahj.2021.10.019.
  7. Lavrynenko O., Santos H., Garza A., Qazi R., Cobos L. Euglycemic Diabetic ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor. Austin Endocrinol Diabetes case Rep. 2021; 6(1): 1018.
  8. Lavrynenko O., Alatrach M., Abdul-Ghani M., Cersosimo E., Puckett C., Alkhouri N., DeFronzo R., Adams J., Vasquez J., Clarke G. Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM. Diabetes 2020 Jun; 69 (Supplement 1): 184-OR. https://doi.org/10.2337/db20-184-OR.
Call 210-358-7500 to request an appointment with this doctor.

Patient reviews

    Download Our Mobile App

    Access health information, get turn-by-turn navigation in University Hospital, find a doctor or location, and more.